The Brief

UCL and uniQure report the first treatment to slow Huntington’s disease with gene therapy AMT-130.

High-dose patients had 75% less progression over three years compared with standard care.

uniQure will seek FDA approval next year, with UK and EU applications to follow.

LONDON - Researchers in London said they have successfully treated Huntington's Diease, a first in the medical world.

The gene responsible for Huntington’s disease was identified in 1993, yet until now, no effective therapies had been available to prevent or slow its progression.

RELATED: Pfizer boosts push for obesity treatments with $4.9B deal for Metsera

What is Huntington's Disease?

Dig deeper:

Huntington's disease is a fatal, inherited disorder that causes nerve cells in parts of the brain to gra

See Full Page